Scarica l'app Stockscreener
34.68
3.32%
-1.19
Dopo l'orario di chiusura:
34.68
Precedente Chiudi:
$35.87
Aprire:
$35.93
Volume 24 ore:
1.08M
Relative Volume:
0.62
Capitalizzazione di mercato:
$4.47B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-7.5391
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
-2.91%
1M Prestazione:
+6.45%
6M Prestazione:
-60.89%
1 anno Prestazione:
-58.16%
Intervallo 1D:
$34.66
$35.93
Intervallo di 1 settimana:
$34.66
$37.00
Portata 52W:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
34.68 | 4.73B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Should I hold or sell Vaxcyte Inc. stock in 2025Best Dividend Insights For Fast Growth - jammulinksnews.com
What institutional investors are buying Vaxcyte Inc. stockChart Pattern Ideas For Fast Growth - jammulinksnews.com
What is the risk reward ratio of investing in Vaxcyte Inc. stockInvest smarter with daily stock recommendations - jammulinksnews.com
What are analysts’ price targets for Vaxcyte Inc. in the next 12 monthsSmart Portfolio Ideas For Fast Growth - jammulinksnews.com
Is Vaxcyte Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - jammulinksnews.com
How strong is Vaxcyte Inc. company’s balance sheetPhenomenal investment performance - jammulinksnews.com
Is Vaxcyte Inc. a growth stock or a value stockRemarkably fast returns - jammulinksnews.com
What catalysts could drive Vaxcyte Inc. stock higher in 2025Rapid growth trajectories - jammulinksnews.com
When is Vaxcyte Inc. stock expected to show significant growthGet insider insights into market trends - jammulinksnews.com
Is it the right time to buy Vaxcyte Inc. stockCapitalize on fast-moving trading opportunities - jammulinksnews.com
What analysts say about Vaxcyte Inc. stockExceptional ROI - PrintWeekIndia
What drives Vaxcyte Inc. stock priceHigh-yield trading alerts - Autocar Professional
Vaxcyte Inc. Stock Analysis and ForecastRapid market gains - jammulinksnews.com
Is Vaxcyte Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) - MSN
Nisa Investment Advisors LLC Buys 293 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
How the (PCVX) price action is used to our Advantage - news.stocktradersdaily.com
Vaxcyte’s High-Stakes Bet On Next-Gen Pneumonia Vaccines - Finimize
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vaxcyte Inc Azioni (PCVX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
10.28%
2.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):